UK prescribing
This article was originally published in The Tan Sheet
Executive Summary
The British Medical Association has called for an "urgent meeting" with British Health Secretary Patricia Hewitt following the UK's announcement to grant prescribing powers to nurses and pharmacists. Hewitt said Nov. 10 that nurses and pharmacists will be afforded prescribing rights for any medical condition, excluding controlled drugs, beginning in Spring 2006 if they complete additional training (1"The Tan Sheet" Nov. 21, 2005, In Brief). "It is difficult to see how healthcare professionals who are not trained to diagnose disease can safely prescribe appropriate treatment," BMA Chairman James Johnson states in a release. Central Consultants & Specialists Committee Chairman Paul Miller called the decision an "irresponsible and dangerous move. Patients will suffer. I would not have me or my family subject to anything other than the highest level of care and prescribing, which is that provided by a fully trained doctor"...
You may also be interested in...
UK prescribing rights
Pharmacists and nurses in the UK have been granted the ability to prescribe any licensed medication for any medical condition, except for controlled drugs, beginning in Spring 2006, British Health Secretary Patricia Hewitt announces Nov. 10. Nurses and pharmacists would be required to undergo training and registration to gain prescribing privileges, the Department of Health states. "By expanding traditional prescribing roles, patients can more easily access the medicines they need from an increased number of highly trained health professionals," Hewitt states. The Medicines & Healthcare products Regulatory Agency requested comments on extended prescribing rights in March (1"The Tan Sheet" March 14, 2005, p. 17)...
Amgen/AstraZeneca’s Tezepelumab Cuts Asthma Exacerbations By 56%
Data presented at AAAI meeting show reduced annualized asthma exacerbation rates across all patient populations, but doctors are unlikely to switch patients served well by existing biologics.
Sarepta’s Next-Generation Drugs Draw Attention Amid ‘Incremental’ Approval
The RNA drug’s accelerated approval brings Sarepta’s exon-skipping market share to nearly 30%.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: